4basebio plc (4BB), the UK-listed biotechnology company, has disclosed a major shareholding notification confirming that Aberdeen Group plc has crossed a significant voting rights threshold. The TR-1 filing, submitted on 11 November 2026 and reflecting positions as at 10 November 2026, shows Aberdeen Group plc now holds 7.571253% of voting rights in 4basebio plc, representing 1,456,310 shares. The threshold was crossed following the completion of a placing on 10 November 2026, making Aberdeen Group one of the company's most significant disclosed institutional shareholders. Investors will be watching what this increased institutional commitment signals about confidence in 4basebio's ongoing strategy.

Key Points

  • 4basebio plc (4BB), ISIN GB00BMCLYF79, is the issuer subject to this major holdings notification
  • Aberdeen Group plc crossed the 5% notifiable voting rights threshold, reaching 7.571253% on 10 November 2026
  • Aberdeen Group holds 1,456,310 direct voting rights; no voting rights are held through financial instruments
  • Investors should watch for any further changes in institutional positioning or subsequent TR-1 filings from Aberdeen Group

Aberdeen Group Reaches 7.57% Stake in 4basebio Following Completed Placing

The notification confirms that Aberdeen Group plc, headquartered in Edinburgh, United Kingdom, acquired voting rights sufficient to cross the 5% notifiable threshold as a result of participating in a placing that completed on 10 November 2026. All 1,456,310 shares are held as direct voting rights under DTR5.1, with zero voting rights held through financial instruments. The disclosure was filed with 4basebio plc on 11 November 2026, one day after the threshold-crossing date, in accordance with standard UK regulatory requirements for major shareholding notifications.

How abrdn Holdings and abrdn Inc. Effectively Control the 4basebio Position

The announcement states that the voting rights are managed through a chain of controlled undertakings beneath Aberdeen Group plc. Specifically, the intermediate holding company abrdn Holdings Limited and the investment management entity abrdn Inc. are identified as the entities through which voting rights are effectively held. The additional information section of the filing clarifies that the shares are managed across multiple discretionary portfolios on behalf of underlying clients, under investment management agreements whereby clients have delegated the exercise of voting power to the referenced investment manager, abrdn Inc., which holds a 7.571253% total stake.

4basebio Placing Completion on 10 November 2026 Triggers Regulatory Disclosure

The TR-1 form confirms that the trigger for this notification was 4basebio plc's placing, which completed on 10 November 2026. The participation of abrdn Inc. in that placing pushed the combined indirect holding above the 5% notifiable threshold under the UK's Disclosure Guidance and Transparency Rules. This filing represents the first disclosed notification from Aberdeen Group plc at this level, as no previous notification position is listed in the form. The completion of the placing and the resulting increase in Aberdeen Group's stake underlines institutional appetite for the transaction.